Under the agreement, Median will offer advanced integrated image services to Quintiles to strengthen Quintiles’ full range of services to accelerate oncology drug development.
Quintiles Oncology Therapeutic Delivery Unit vice president Anne Pilling said this partnership complements their current portfolio of imaging solutions and provides further proof of their commitment to provide biopharma and healthcare service providers with the tools, expertise and services needed to increase productivity and better the lives of patients.
Median CEO Fredrik Brag said this collaboration will result in better quality of data, increased awareness for biopharma for go/no-go decisions along the drug development stages, and ultimately more robust regulatory submission to health agencies.
